Century Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $109.2M | $6.6M | $2.2M | $5.2M | — |
| Operating income | -$17.3M | -$138.1M | -$146.5M | -$133.8M | -$94.9M |
| Operating expenses | $126.4M | $144.7M | $148.8M | $139.0M | $94.9M |
| Cash from operations | -$103.9M | -$110.1M | -$88.3M | $14.1M | -$89.0M |
| Capital expenditure | $848,000 | $154,000 | $13.7M | $30.6M | $45.0M |
| Free cash flow | -$104.7M | -$110.3M | -$102.1M | -$16.6M | -$134.0M |
| Impairments | $6.8M | $4.3M | $16.4M | — | — |
| Total assets | $223.7M | $353.2M | $360.7M | $486.5M | $437.4M |
| Total liabilities | $64.8M | $191.9M | $175.9M | $183.8M | $41.1M |
| Total debt | — | — | — | $10.0M | $10.0M |
Shares outstanding 180.4M · Free float 89.2%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.